RxDoctor Payments Data

Harvey Watts, MD

Gastroenterology · San Francisco, CANPI 1184640872

Payments from drug & device makers

$685in general payments, 2019–2025

Across 35 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$298
  • Takeda Pharmaceuticals U.S.A., Inc.$111
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$106
  • Kerecis Limited$44
  • Pfizer$23
  • Novo Nordisk$21
  • plus $83 from 6 others

What the payments were for

  • Food & beverage$685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)15$298
Takeda Pharmaceuticals U.S.A., Inc.6$111
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$106
Kerecis Limited1$44
Pfizer1$23
Novo Nordisk1$21
IBSA Pharma Inc.1$16
Concordia Pharmaceuticals Inc.1$15
Alfasigma USA, Inc.1$15
Merck1$13
Braintree Laboratories, Inc.1$13
AstraZeneca1$12

How this compares

$685 in reported general payments places this provider in the 30th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$175,359
Medicare patients
224
Services billed
2,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$73,644
CreonLipase/Protease/Amylase15$20,783
MyrbetriqMirabegron22$19,734
LinzessLinaclotide20$17,478
OzempicSemaglutide16$14,988
PremarinEstrogens, Conjugated16$9,633
Mesalamine17$7,626
Sumatriptan Succinate13$6,756
Dexlansoprazole DrDexlansoprazole20$4,838
Mesalamine DrMesalamine18$4,716
MovantikNaloxegol Oxalate11$4,297
Wixela InhubFluticasone Propion/Salmeterol12$2,200
Metoprolol Succinate109$2,002
SynthroidLevothyroxine Sodium25$1,950
PaxlovidNirmatrelvir/Ritonavir27$1,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$23$84,645105 claims
AbbVieCreon, Linzess, Synthroid$298$40,21060 claims
Novo NordiskOzempic$21$14,98816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →